Health and Healthcare
The system that touches every life. The cost crisis nobody can solve, the aging math, the pandemic lessons mostly unlearned, and the AI revolution arriving in clinic.
(roughly 10% of total world economic activity)
(roughly twice the developed-country average)
(up from about 50 in 1960; roughly flat since the pandemic)
A note on framing. Healthcare is one of the topics where almost every reader has personal experience that contradicts at least some of the policy story they have been told. The page below tries to walk through the structural picture - what countries actually spend, what they get for it, where the system is moving - in a way that respects the reader's intelligence regardless of their politics. There is no clean ideological answer to the healthcare question; there are real trade-offs that different societies have made differently, and the data on which approaches deliver what is more useful than the slogans usually suggest.
The size of the global healthcare bill
The world spends roughly $10 trillion a year on healthcare - about a tenth of the total economy. That share has been rising in nearly every country for decades, faster than the overall economy in most cases. There is no developed country where healthcare's share of national income has fallen meaningfully over the last fifty years. Healthcare is one of the few things humans want more of as we get richer, and that has a structural effect on every public budget.
Within that global total, the picture is sharply uneven. The United States alone spends about $4.8 trillion - close to half of the world's total - on its 4% of the world's population. The next-largest spenders (China, Japan, Germany, France, the UK, all collectively) make up roughly the next quarter. The rest of the world, including all of Africa, all of South Asia, most of Southeast Asia, and most of Latin America, splits the remaining quarter. By spending per person the differences are enormous: the US around $14,000 a year, most rich European countries between $5,000 and $7,000, China about $750, India about $90, much of Sub-Saharan Africa under $50.
The gap between what a country spends and what it gets is the central puzzle of comparative healthcare economics. Spending more does not automatically buy more health. Costa Rica with about $1,000 per person achieves life expectancy near 80. Cuba with even less achieves similar numbers. Several rich European countries with half of US per-person spending have longer average lives. Singapore spends about $4,000 per person on healthcare and has one of the world's longest life expectancies. The relationship between spending and outcome is loose at best, and that is one of the most important facts in the field.
The aging math behind everything
The single most powerful structural force on global healthcare over the next thirty years is aging. The number of people over 65 is rising in every region (with a small lag in Sub-Saharan Africa). Medical spending per person rises sharply with age - roughly three to five times as much per year on care for someone over 75 as for someone in their 40s. As populations age, the per-person spending rises even when individual care patterns do not change.
The math runs into hard ceilings everywhere. Most pay-as-you-go pension and healthcare systems were built when there were four or five working-age adults per retiree. They are now drifting toward two and a half to three. By 2050 the developed-world ratio will be in the high 1s in many countries. The taxes and contributions that working-age adults pay cannot rise fast enough to keep the same per-retiree spending without a much larger underlying economy or sharply higher productivity. Something has to give: benefits, taxes, retirement age, immigration, or some combination.
Each developed country is solving this in its own way, with different politics. Germany, Japan, and Italy are slowly raising retirement ages and tightening benefits. France has done less of either, and its 2023 pension-reform protests showed how politically expensive the choices are. The US has not yet seriously addressed Medicare's projected shortfall, with the trust fund expected to be depleted within a decade. The UK's NHS has been under chronic funding stress as more of the population ages into heavier use. None of these is a crisis this year. Each is a slow-moving structural force that will dominate domestic politics for decades.
How country systems actually compare
The healthcare systems of different rich countries differ in ways that affect both costs and outcomes. The numbers below are rough, drawn from OECD and World Bank data, and approximate to give a comparative sense rather than precise current figures.
The takeaway: every developed country except the US has built a system that achieves universal coverage at substantially lower cost than the US, with comparable or better health outcomes. The specific structure varies (single-payer in Canada, multi-payer in Germany, mandatory insurance in Switzerland, mandatory savings in Singapore) but each delivers what most Americans would consider the central goal of healthcare reform. The US uses more healthcare resources for a smaller share of the population at higher prices than any peer country, and the structural reasons are well-documented even when politically difficult to address.
Why US healthcare costs are different
The American cost gap is the single largest healthcare-policy puzzle in the developed world. Multiple research traditions have studied it, and the consensus is reasonably clear: the gap is mostly about prices, not utilisation. Americans do not get more healthcare than residents of comparable countries; they pay more for each unit of care.
Some specific drivers. Drug prices in the US are typically two to three times what the same drugs cost in peer countries, because Medicare has been legally restricted from negotiating prices for most of its history (a restriction that has been partially reformed since 2022 but not fully). Hospital charges are not standardised; the same procedure can cost wildly different amounts at different facilities and for different patients. Administrative overhead consumes roughly a quarter to a third of healthcare spending in the US versus a fraction of that in most single-payer systems, because every claim has to be negotiated separately between thousands of providers and hundreds of insurers. Specialist physicians earn more in the US than in any peer country. Medical malpractice and defensive medicine add costs that other countries handle differently.
None of these is the single decisive factor. Together they add up to a roughly $1.5 trillion a year cost premium that the US pays without obviously better outcomes. The political reason this is hard to fix is straightforward: every dollar of "waste" is revenue for someone - a hospital, an insurer, a drug company, a specialist - and each constituency has lobbyists, campaign contributions, and genuine arguments for why their slice of spending is justified. The system is sticky in the same way the wealth-concentration system covered elsewhere on this site is sticky: too many specific actors benefit from the current arrangement to make broad reform easy.
The pandemic and what was learned
The COVID-19 pandemic killed roughly seven million people globally according to official counts, with excess-mortality estimates running considerably higher (15-25 million depending on methodology). It produced the deepest global recession since World War II, the most rapid vaccine development in history, and a body of policy lessons that have been only partially absorbed.
What worked: rapid mRNA vaccine development built on years of underlying research; emergency genomic sequencing networks; the World Health Organization's coordination role despite its political constraints; some specific national responses that combined competent public-health communication with adequate hospital capacity (Korea, Taiwan, New Zealand, Vietnam in the first year). What did not work as well: the global cooperation needed to get vaccines to lower-income countries quickly; the public-health communication in many countries; pandemic preparedness investments that had been promised after SARS-1, Ebola, and H1N1 but were largely not made; the political durability of public-health measures once the emergency phase passed.
The longer-run effects are still unfolding. Trust in public-health institutions has fallen in most countries (covered in the Trust piece on this site) and this matters for the next pandemic, which is not a question of if but when. Pandemic-preparedness funding rose for a few years after 2020 and has been falling again in most countries. The Pandemic Treaty being negotiated under the WHO has stalled. The probability of another major pandemic-scale event in the next 20 years is widely estimated at well over 50%, and the world's preparation for it is structurally lower than it was in early 2020 in some specific dimensions and structurally higher in others (genomic surveillance, vaccine platforms). Whether the next pandemic is handled better than COVID-19 depends on choices that are not currently being made.
AI and the new clinic
Artificial intelligence is reaching healthcare delivery at scale, and the implications are starting to be visible. Large-language-model-based assistants are being deployed in clinical documentation (where doctors spend a substantial portion of their time on paperwork), diagnostic support (where AI image analysis has matched specialists in some narrow domains), drug discovery (where AlphaFold has changed how protein structures are computed), and patient triage (where AI-aided early diagnosis is being trialled in primary care).
The promise is real: documentation burden reduction would free clinician time for actual care; better diagnostic support could reduce errors that cause measurable harm; drug discovery acceleration could meaningfully lower costs. The risks are also real: AI errors in clinical settings have specific liability and safety implications, the data on most AI medical tools is still thin, and there is a meaningful chance of substituting AI's confident wrongness for human uncertainty in ways that produce worse outcomes rather than better. The deployment so far has been faster in administrative and supportive functions and slower in directly clinical ones, which is the right pattern given the stakes.
Two specific changes are likely over the next decade. The first is dramatic improvement in radiology, pathology, and dermatology - fields that involve pattern recognition on images where AI is already approaching specialist-level performance on common cases. The second is a quiet expansion of AI-aided primary care in lower-income countries where specialist scarcity is acute. Combined with the global rise of telemedicine since the pandemic, this could meaningfully improve healthcare access for people who currently have very limited access to specialists. Whether the developed-world clinical workflow changes as fundamentally is less clear; the regulatory, liability, and cultural barriers are higher.
The paths from here
Healthcare is unusual among the topics on this site in that it changes slowly and predictably until it changes suddenly. Each path below is one realistic shape the next two decades could take.
US healthcare slowly evolves
The US system continues its slow accretion of partial reforms - drug-price negotiation expanded, more states using their authority to control costs, more employers experimenting with reference-pricing and direct-contracting, gradual expansion of Medicare-style options for under-65 adults. No comprehensive overhaul; many incremental changes. By 2040 the system is materially different from today without ever being formally restructured.
Will it happen? This is the base case for the US given its political structure. The Affordable Care Act of 2010 was the largest single change in 50 years and was incremental within the existing structure. Future changes are most likely to be similar - real and consequential without being transformational.
The aging cost wave hits
By the early 2030s the cost pressures on Medicare, the NHS, and equivalent systems become impossible to defer. Some combination of higher contribution rates, reduced benefits, raised retirement ages, and rationing of expensive end-of-life care becomes the actual policy in most developed countries. The political conflict over which group bears which cost is the dominant domestic policy story of the decade.
Will it happen? Some version is virtually certain. The math simply does not work otherwise. The form the response takes will vary enormously by country - some through formal policy, some through quiet erosion, some through crisis-driven reform after a system is forced to default on commitments. Few countries have started the politics of this seriously.
Pandemic risk grows quietly
Without sustained investment in pandemic preparedness, the world becomes more rather than less vulnerable to the next major outbreak. Genomic surveillance networks fray. Antibiotic resistance worsens. Investment in vaccine platforms slows. When the next pandemic arrives, the world handles it less well than it did COVID-19.
Will it happen? The trajectory points this way absent serious investment that is not currently happening. The good news is that the technical capacity built during COVID-19 (mRNA platforms, sequencing networks, diagnostic ramping) does not fully disappear; the bad news is that the political infrastructure for using it has weakened. The probability of a worse-handled next pandemic is meaningful and rising.
AI quietly transforms primary care
By the early 2030s, AI-aided diagnosis, decision support, and patient interaction become routine across most healthcare systems. Specialist-quality care becomes available remotely in lower-income countries. Documentation burden falls and clinician time shifts toward direct patient interaction. Rising productivity in healthcare partially offsets the aging cost wave.
Will it happen? Some version is likely. The pace depends on regulatory choices, on whether AI systems can demonstrate the safety records that medicine reasonably demands, and on whether the savings flow through to lower costs or get absorbed by other parts of the system. The most plausible version is uneven - faster in some specialties and countries than others.
Drug-price reform spreads
The US's gradual reform of Medicare drug-price negotiation expands to more drugs, more programmes, and possibly to broader price-setting authority. Other rich countries continue to negotiate aggressively. The pharmaceutical industry's profit model shifts from US-paid premium prices toward something more globally similar. Drug innovation continues but at lower margins.
Will it happen? Already partly happening. The 2022 Inflation Reduction Act in the US started this, and the implementation is ongoing. The pharmaceutical industry will resist further expansion vigorously; whether the politics holds depends on how the cost-versus-innovation argument plays out and on how much real innovation actually slows when prices fall.
Mental healthcare expands meaningfully
The mental-health crisis covered separately on this site (see the Mental Health page) drives sustained expansion of the mental-health system. Telehealth, AI-aided therapy aids, group-treatment programmes, and integration of mental-health support into primary care all grow. Treatment access improves materially even as the underlying problem may not.
Will it happen? Already partly happening. Insurance coverage of mental-health care has expanded in most rich countries. The supply of clinicians is the binding constraint and is hard to scale quickly. AI may help on the supply side; whether it helps with the actual outcomes is genuinely uncertain.
Global healthcare divergence widens
The healthcare gap between richer and poorer countries widens further as aging-related cost pressures crowd out international health spending and as the next set of expensive medical breakthroughs (gene therapies, advanced cancer treatments, precision medicine) become available primarily to wealthy patients. The Sub-Saharan African and South Asian healthcare gap with the rest of the world grows even as overall outcomes continue to improve.
Will it happen? The trajectory points this way absent specific countervailing policy. International health funding has been falling in real terms in most donor countries since 2020. The next generation of expensive treatments will be largely available only to wealthy patients in wealthy systems. The global health story over the next twenty years has both real progress and real divergence in it.
The realistic forecast is, again, a mix. The base case is slow drift in the US system, aging cost pressures hitting most rich countries by the late 2020s, AI gradually reshaping clinical practice, and drug-price reform expanding incrementally. The downside scenarios (worse pandemic handling, widening global divergence) are real but not certain. The healthcare story is more determined by demographics and politics than by technology, and the demographics are largely fixed for the next twenty years.
Where serious analysts disagree
Healthcare is one of the topics where careful researchers using similar data reach different conclusions about what to do. Each reading below is held by named scholars worth engaging directly.
The US system is structurally exceptional and very hard to fix
The US healthcare cost premium is not a bug that can be fixed through better policy at the margins. It is the predictable result of a system in which most spending happens through private intermediaries with strong political constituencies, in which prices are not set by any central authority, and in which the political coalitions needed to reform the system have repeatedly failed for sixty years. Significant reform requires a level of political consensus that has not existed in living memory and probably will not appear without a major crisis.
Held by: Aaron Carroll (Indiana), Atul Gawande (Harvard), and a substantial fraction of US health-policy researchers. Their position is uncomfortable politically but well-supported by the comparative data and the history of US reform attempts.
The cost crisis is mostly about prices, not utilisation
Americans do not get more healthcare than peer countries; we pay more for each unit. Reform that focuses on reducing utilisation (managed care, prior authorisation, deductibles, copays) misses the actual problem and produces its own harms. Reform that focuses on prices (Medicare drug negotiation, hospital price transparency, all-payer rate setting) addresses the actual cost driver.
Held by: Uwe Reinhardt (the late Princeton health economist whose framing has shaped the field), Sherry Glied (NYU), and a body of price-focused health economics research. Their case is supported by the international comparison data and the limited success of utilisation-focused reforms.
Healthcare is fundamentally improvable through technology
The pessimism about healthcare reform misses the most important variable: the field is on the cusp of substantial productivity gains from AI, genomics, advanced imaging, and personalised medicine. Treating the cost-and-access problem as a static distributional fight ignores the possibility that improving the underlying technology meaningfully shifts the constraint set. The next 20 years will look more different from the previous 20 than the previous 20 looked from the 20 before that.
Held by: Eric Topol (Scripps), and a tradition of technology-optimist healthcare analysis. Their case is strongest on diagnostic and informational dimensions and weakest on the parts of healthcare that depend on human-time-intensive care that AI does not directly substitute for. Both sides are partly right.
Pandemic preparedness has not improved and is in some ways worse
The political coalition for sustained pandemic-preparedness investment has eroded since 2022. The Pandemic Treaty is stalled. Genomic-surveillance networks have fragmented. The institutions that worked partially well during COVID-19 (the WHO, the CDC, the EMA) have lost trust and resources. The next pandemic will arrive in worse strategic conditions than COVID-19 did.
Held by: Larry Brilliant (epidemiologist who helped eradicate smallpox), Bill Gates (in his foundation work), and a body of careful pandemic-policy analysis. Their warnings have been consistent and have so far not been followed by adequate response. The argument is uncomfortable but well-supported.
Universal healthcare is achievable politically in the US given the right framing
Polling consistently shows majority US support for universal healthcare in the abstract. The political failure has been in translating that abstract support into specific reforms that survive the lobbying response. With the right framing - specifically, building on Medicare expansion rather than replacing the employer system, and framing the reform as cost reduction rather than coverage expansion - meaningful progress is more politically possible than a generation of failed reform attempts suggests.
Held by: Paul Krugman, Henry Aaron (Brookings), and a strand of progressive health-policy thinking. Their argument has been around for decades; whether the political conditions for it are improving or worsening is contested.
None of these readings is fully right or wrong. What can be said from the available evidence: the US system is structurally exceptional and hard to fix at scale; price-focused reform is more promising than utilisation-focused reform; technology will help but not as much as enthusiasts hope; pandemic preparedness is genuinely deteriorating; and universal coverage in the US is more politically constrained than the abstract poll numbers suggest. Healthcare is one of the topics where the structural conditions matter more than the policy details.
What this means for you
Healthcare is among the most personally relevant topics on this site. A few practical observations:
If you live in the United States
Your healthcare is structurally more expensive and more uncertain than residents of any peer country face. Maintaining continuous insurance coverage, understanding your specific plan, building a relationship with a primary-care physician who knows your history, and saving against the high deductibles and out-of-pocket exposures American plans typically include are all worthwhile in ways that they would not be elsewhere. The system is not going to fix itself in time to help you personally; planning around its actual structure is more useful than waiting for reform.
If you are aging or care for an aging parent
Long-term care is the largest healthcare cost most families encounter, and it is structurally underinsured in almost every system. Long-term care insurance is expensive, has narrowed in availability, and produces mixed results when it pays out. Government programmes pay for some long-term care but typically only after assets are exhausted. Family caregiving (mostly by adult daughters and daughters-in-law) absorbs much of the burden invisibly. Talking about long-term care preferences with aging parents before a crisis - including end-of-life choices - is uncomfortable and is one of the most consequential family conversations most people have.
If you have employer healthcare
Most American workers have insurance tied to their job, which produces complex implications most workers do not fully think through. Job changes mean insurance changes (and possibly new deductibles starting over). Self-employment, retirement before Medicare age, and gaps between jobs all carry healthcare risk that is hard to plan around. The structure subsidises larger employers (who can negotiate better insurance) over small ones, and rewards staying in jobs that are otherwise no longer the best fit. None of this is your fault as an individual; understanding it helps you plan around it.
If you live outside the United States
Your country probably delivers healthcare more efficiently and more universally than the US, but each system has its own pressures - the NHS waiting lists, the European cost escalations, the Asian aging math. Engaging with the specific debates in your country (rather than the simpler "we're better than the US" framing) is more useful. Most of the rich-country healthcare systems are under structural stress that will produce real changes over the next decade; what those changes look like depends on local politics that benefit from informed citizen engagement.
If you work in technology or healthcare
The intersection of AI and healthcare is one of the largest single opportunities in technology over the next decade, with serious challenges around safety, regulation, and clinical workflow. Clinical training programmes, healthcare-management roles, and the technology-meets-medicine intersection are all growing areas of need. The supply of trained clinicians is structurally tight in most rich countries; the supply of people who can responsibly bridge clinical and technical worlds is even tighter. Anyone with both skill sets is in unusually high demand.
The mechanics behind this
The healthcare story sits on top of three deeper mechanisms covered elsewhere on this site. If the analysis above depends on ideas you want to understand first, these fundamentals make the conversation more legible:
